Discover
etrasimod (APD334) / ArenaEtrasimod: Completion of enrollment of P3 ELEVATE UC 52 trial (NCT03945188) for ulcerative colitis in H2 2020 (Arena) - Jun 4, 2020 - Corporate Presentation: Data from P3 ELEVATE UC 12 trial (NCT03996369) for ulcerative colitis in H2 2021
etrolizumab (RG7413) / RocheA Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2) (clinicaltrials.gov) - Jun 4, 2020 - P3; N=358; Completed; Sponsor: Hoffmann-La Roche; Active, not recruiting --> Completed
Zeposia (ozanimod) / BMSBristol Myers Squibb announces positive topline results from pivotal phase 3 True North trial evaluating Zeposia (ozanimod) in patients with moderate to severe ulcerative colitis (Businesswire) - Jun 2, 2020 - P3, N=1,012; True North (NCT02435992); Sponsor: Celgene; "Bristol Myers Squibb (NYSE:BMY) today announced results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod)...for adult patients with moderate to severe ulcerative colitis. True North met both primary endpoints, demonstrating highly statistically significant (p-value < 0.0001) results for induction of clinical remission at Week 10 and in maintenance at Week 52....The company will complete a full evaluation of the True North data and work with investigators to present detailed results at a future medical meeting, as well as discuss these results with health authorities."
Stelara (ustekinumab) / J&JUK Health Agency recommends Stelara for moderately to severely active ulcerative colitis (IBD News Today) - Jun 1, 2020 - "The U.K. National Institute for Health and Care Excellence (NICE) has recommended the use of Stelara (ustekinumab) to treat patients with moderately to severely active ulcerative colitis specifically in adults when conventional and biological therapies are ineffective or not tolerated. Stelara's developer, Janssen, anticipates that this recommendation may allow the treatment to be publicly available in England and Wales before the end of 2020."
Zeposia (ozanimod) / BMSTOUCHSTONE: Efficacy and Safety Study of RPC1063 in Ulcerative Colitis (clinicaltrials.gov) - Jun 2, 2020 - P2; N=196; Completed; Sponsor: Celgene; Active, not recruiting --> Completed
